Evidence map›Paper›PMID 40317367›Full record

SynthesisClinical and experimental medicine2025

Cytokine profiles as predictive biomarkers for treatment outcomes in advanced gastric cancer patients undergoing PD-1 blockade immunochemotherapy: a meta-analysis.

Fumeng Yang, Zakari Shaibu, Qian Liu, Wei Zhu

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fumeng YangSchool of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.ORCID http://orcid.org/0000-0002-2636-7340
Zakari ShaibuSchool of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.ORCID http://orcid.org/0000-0003-2318-5936
Qian LiuDepartment of Laboratory Medicine, Lianyungang Clinical College, Jiangsu University & The Second People's Hospital of Lianyungang, Lianyungang, 222006, Jiangsu, China. 15805125083@163.com.ORCID http://orcid.org/0000-0003-1969-5829
Wei ZhuSchool of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China. zhuwei@ujs.edu.cn.

Funding

Key Project of Scientific Research Development Fund of Nanjing Medical University Kangda College KD2023KYJJ048Key Project of the Natural Science Foundation of Bengbu Medical College 2022byzd175Lianyungang aging health research project L202306, L202215Lianyungang Cancer prevention and Treatment Science and Technology Development Program Project MS202309, ZD202306
6 · The paper itself

Abstract

Immunotherapy, specifically PD-1 blockade, is a promising treatment for advanced gastric cancer (AGC). However, predicting patient response is challenging. Cytokines, key immune response regulators, could be important biomarkers for forecasting patient outcomes and susceptibility to PD-1 blockade immunochemotherapy in AGC. This meta-analysis aims to evaluate the potential of cytokine profiles as predictive biomarkers for treatment outcomes in patients with AGC undergoing immunochemotherapy. Meta-analysis. Original studies on the evaluation of various serum samples of cytokines in AGC patients after immunochemotherapy were searched in PubMed, Google Scholar, Embase, Cochrane Library, and Web of Science, with a focus on literature published up to October 31, 2023. Data from multiple studies were pooled to analyze the impact of IL-2, IL-4, IL-6, IL-8, IL-10, and IFN-γ expression on treatment outcomes using RevMan 5.4.1. Prospero ID: CRD42024557837. Five studies were included. In AGC patients receiving immunochemotherapy, high levels of IL-4 were correlated with enhanced PFS following therapy. In contrast, there were no significant differences observed in the expression of IL-2, IL-6, IL-10, and IFN-γ for PFS in AGC after treatment. Notably, elevated IL-6 expression was significantly associated with poorer OS in AGC patients undergoing immunochemotherapy. The findings suggest that expression levels of cytokines, particularly IL-4 and IL-6, play a significant role in predicting treatment outcomes in AGC patients undergoing immunochemotherapy. Further research is warranted to validate these results and elucidate the underlying mechanisms driving these associations.

Indexed as

Biomarkers, TumorCytokinesImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorStomach NeoplasmsHumansTreatment OutcomeBiomarkers, TumorCytokinesImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCytokinesImmune checkpoint inhibitorsInterleukinsPD-1Stomach neoplasm

Identifiers

PMID40317367
PMCPMC12049293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.